Biotechnology is also a vital engine of economic prosperity, generating almost 7% of U.S. private-sector GDP and supporting roughly 10 million jobs across all 50 states. The good news is that we still ...

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA”, the 'Company”), a clinical-stage biopharmaceutical company focused on ...

During the upscaling process, Polyrizon and its manufacturing partner successfully transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to ...

Capital has become discerning. The inflated valuations of 2021 have given way to a more disciplined environment where ...

The prospect of diagnosing cancer through painless methods—such as a simple AI-assisted blood or urine test that detects tiny ...

The SBIO ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness.

The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count ...

Researchers from CIIMAR and the University of Helsinki have discovered a new biochemical modification in natural ...

Biotechnology can be used in the packaging of beauty products and has a significant sustainability impact that is good for ...

Lawmakers are proposing a new effort to strengthen biopharma manufacturing in the U.S., leveraging a bill that seeks to ...

As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...